NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
ER/PR Positive HER2neu Negative Metastatic Breast Cancer
Patient specific case scenarios presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.
Patient case highlights:
In treating an 85-year-old woman presenting with hip pain who was diagnosed with ER/PR positive HER2/neu negative metastatic breast cancer and who underwent a simple mastectomy, 9 of 10 oncologists would recommend xx….To treat her breast cancer, 5 in 10 oncologists would choose…
In a 60-year-old woman with diabetes, hypertension, renal insufficiency, and chronic obstructive pulmonary disease who found a lump in her breast and tests revealed metastatic lesions in ribs, spine, and femur initially treated with…
Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer.
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
• Understand what occurs with actual patients
• Access the most up-to-date prescribing trends
• Gain actionable data for developing and improving your market strategies
• Pinpoint needs of your target audience
• Focus resources to maximize the effectiveness of your budget
• Understand where your product fits
• Understand where your competitor's product fits
Table of Contents
Executive Summary5
Chapter 1: Introduction9
Table 1. Treatment Options in Metastatic Breast Cancer9
Chapter 2: Respondent Demographics11
Table 2. Eligibility Criteria for Survey Participation11
Figure 2.1 Gender of Survey Respondents11
Figure 2.2 Years since Medical School Graduation12
Figure 2.3 Practice Settings12
Figure 2.4 Practices in NCI Cancer Centers13
Figure 2.5 Geographic Settings13
Figure 2.6 Survey Respondents by State's Breast Cancer Mortality14
Figure 2.7 Number of Physicians in Practice Groups15
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen15
Chapter 3: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer16
Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer16
Figure 3.116
Other than analgesics, treatment of patient's hip pain with ER/PR positive HER2/neu negative metastatic breast cancer17
Figure 3.217
Treatment with ER/PR positive HER2/neu negative metastatic breast cancer17
Figure 3.317
Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer18
Figure 3.418
Factors Influencing Treatment Choice with ER/PR positive HER2/neu Negative Metastatic Breast Cancer19
Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer20
Figure 3.520
Chapter 4: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer with Comorbidities21
Confidence managing patient with metastatic breast cancer with multiple comorbidities21
Figure 4.121
Barriers to managing patient, metastatic breast cancer with multiple comorbidities22
Figure 4.222
Treatment in addition to the aromatase inhibitor for patient's metastatic breast cancer with multiple comorbidities24
Figure 4.324
Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities25
Figure 4.425
Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities26
Figure 4.526
Chapter 5: Summary28
Appendix A: Survey Instrument29
Companies mentioned
Celgene, Pfizer, Astra Zeneca, Genentech/Roche, Novartis, Eisai, Eli Lilly, Abbott Labs, Sanofi-aventis, GlaxoSmithKline
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker